AstraZeneca PLC

Nvidia's board authorized an additional $150B for its existing share-repurchase program, bringing the remaining authorization to $235B, which the company said was the largest increase to a share-repurchase authorization in history. Micron Technology reported fiscal fourth-quarter results and guidance that topped Wall Street's expectations by a wide margin, earning an adjusted $33.42 per share as revenue soared 379.1% year-over-year to $54.23B, versus analyst expectations of $31.72 per share on $51.49B in revenue. Accenture shares rose after its Q4 beat expectations and it forecast upbeat fiscal 2027 revenue growth, reporting GAAP earnings of $3.29 per share, revenue up 6.3% year over year to $18.7B, and new bookings of $22.2B. MongoDB shares fell after CEO Chirantan Desai stepped down effective immediately to become the newly created Chief Enterprise Platform Officer at Meta, with the board appointing Dev Ittycheria as interim president and CEO. Summit Therapeutics shares surged after AstraZeneca announced a $2B equity investment in the U.S. biotech and a clinical collaboration to develop new cancer treatments, purchasing convertible preferred shares at a conversion price equivalent to $18.36 per common share, a 10% premium to Summit's five-day volume-weighted average price. For the week, the Dow fell 1.26%, the S&P 500 lost 0.27%, and the Nasdaq Composite climbed 0.45%.

The Trump administration has selected 10 companies, including AbbVie, Amgen, Pfizer, and GSK, for a new pilot program that tests a rebate model for drugs purchased under a federal program benefiting uninsured and low-income patients. The 340B Rebate Model Pilot takes effect on January 1 and allows the selected manufacturers to verify and pay rebates for 21 discounted drugs purchased under the government's 340B drug pricing program, rather than offering savings upfront as under the current discount model. The participating drugmakers are AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers, GSK, Merck, Pfizer, and Teva. The Health Resources and Services Administration, the HHS unit overseeing the program, said the approach helps address compliance concerns proactively rather than relying primarily on retrospective reviews, audits, and dispute resolution processes. The pilot marks the Trump administration's second attempt to overhaul the decades-old drug discount program, after a federal judge blocked HRSA's first 340B rebate pilot following a case brought by hospital groups last year.

AstraZeneca PLC, Daiichi Sankyo and Summit Therapeutics announced clinical collaboration agreements to test ivonescimab in combination with Datroway and sonesitatug vedotin across multiple tumour types, starting with a planned Phase III trial in first-line triple-negative breast cancer and gastrointestinal cancer. AstraZeneca's approximately US$2.00 billion equity investment via convertible preferred stock, alongside the co-funded oncology trials, prices the preferred stock at an implied US$18.36 per common share and targets roughly a 12% ownership stake in Summit. All parties retain full rights to their respective medicines. The investment strengthens Summit's funding and combination profile ahead of the HARMONi and HARMONi-3 readouts, though the U.S. FDA decision on the HARMONi BLA remains the key near-term catalyst and central source of risk. Summit's narrative projects $1.3 billion revenue and $223.0 million earnings by 2029, while some optimistic analysts model about US$2.7 billion of revenue and nearly US$289 million of earnings by 2029.

AstraZeneca and Daiichi Sankyo have entered a clinical trial collaboration agreement with Summit Therapeutics to evaluate Datroway, also known as datopotamab deruxtecan, in combination with Summit's ivonescimab across multiple tumor types. The companies plan to begin with a phase 3 trial in first-line triple negative breast cancer. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. Under the agreement, each company will contribute its respective compound for the planned combination trials, which will be sponsored by AstraZeneca or Daiichi Sankyo. AstraZeneca, Daiichi Sankyo and Summit will each contribute to trial costs, and each company will retain development and commercial rights to its respective medicines.

AstraZeneca said the FDA has granted Priority Review to a supplemental Biologics License Application for IMFINZI with enfortumab vedotin in muscle-invasive bladder cancer. The application targets patients who are ineligible for or decline cisplatin-based chemotherapy, a group with limited treatment choices. Priority Review shortens the FDA review timeline for this regimen, reflecting the agency's view that it may offer a meaningful clinical advance. AstraZeneca, a £192.8 billion pharmaceuticals group focused on prescription medicines, has been building its oncology presence across several tumour types, so any potential label expansion for IMFINZI touches a core therapy area rather than a side project for the business.

AstraZeneca has filed a New Drug Application with the US FDA for combining ORPATHYS and TAGRISSO in a specific form of advanced non small cell lung cancer after EGFR TKI treatment. The filing comes as the company's shares have fallen 10.29% over 90 days and 8.56% year to date, though the 1 year total shareholder return of 13.04% and 5 year total shareholder return of 55.73% remain positive. The most followed analyst narrative puts fair value at £159.11 against a last close of £124.28, implying 22% undervaluation, with 206 investors backing that view. Management estimates its late-stage pipeline across oncology, rare diseases, and cardiovascular and metabolic therapies could generate $10+ billion in peak risk-adjusted revenue. Risks to the rerating include tighter drug pricing regimes in key markets and heavier pressure on blockbuster franchises as competition builds.

On September 29, Summit announced that AstraZeneca will make a strategic equity investment of $2 billion in the company and will take the lead in advancing clinical research on ivonescimab combined with AstraZeneca's Sonesitatug Vedotin for the treatment of multiple gastrointestinal tumors. The two parties also plan to further promote clinical exploration of combination therapies involving ivonescimab and a range of AstraZeneca antibody-drug conjugates and other anti-tumor drugs. Boosted by this news, innovative drug concept stocks were repeatedly active in early trading on September 30. CanSino Biologics hit the 20-cent daily limit up, Berry Genomics hit the daily limit up, and Sino Biological, Tri-Prime Gene, and Walvax Biotechnology quickly followed with gains. On the same day, China's three major A-share indices opened collectively higher. As of press time, the Shanghai Composite Index rose 0.35 percent, the Shenzhen Component Index rose 0.48 percent, the ChiNext Index rose 0.92 percent, and the SSE STAR 50 Composite Index rose 0.31 percent. By sector, biotechnology, power generation equipment, and gas were relatively active, while the real estate sector led declines, and internet, semiconductor, and software sectors fluctuated in adjustment.

Dizal Pharmaceutical announced that on July 14, 2026, it signed a license agreement with AstraZeneca, granting AstraZeneca exclusive global rights to develop and commercialize sunvozertinib. The agreement took effect on August 31, 2026, and the company recently received a $600 million upfront payment from AstraZeneca. Boosted by this news, as of 10:09 a.m. on September 30, 2026, the underlying index of the Penghua STAR Market Healthcare ETF, the SSE STAR Market Biomedical Index, rose 2.85%, with constituent stocks CanSino Biologics up 20.00%, Vazyme up 11.89%, and Anhui Huaheng Biotechnology up 8.45%. The underlying index of the Penghua Hong Kong Stock Connect Healthcare ETF, the CSI Hong Kong Stock Connect Healthcare Composite Index, rose 2.16%. In addition, the latest post-hoc analysis of the Phase 3 clinical study in China of telitacicept for generalized myasthenia gravis, published on September 29, showed that more than 94% of patients achieved at least a 5-point improvement in MG-ADL score, and among patients who achieved MSE, 86.7% maintained MSE status at the next monthly assessment. Orient Securities pointed out that improving industry profit margins and the ramp-up of innovative products are jointly driving profit release, with CXO and innovative biologics becoming the strongest boom sectors. If innovative drugs continue to deliver profits in the second half of the year and CXO orders smoothly translate into revenue, the market's pricing logic for the pharmaceutical sector is expected to shift from low-valuation repair to a reassessment of the earnings sustainability of high-quality growth assets.

Hengrui Medicine announced that it has signed a licensing agreement with Novo Nordisk for the HRS-1596 project, granting the global weight-loss drug leader Novo Nordisk rights to its independently developed HRS-1596. The potential total transaction value is up to 2.6 billion US dollars, marking another step forward for Chinese innovative drug companies in the global weight-loss sector. On the same day, Dizal Pharmaceutical announced that it recently received a 600 million US dollar upfront payment from AstraZeneca. Boosted by this news, on September 30, the medical services concept rose 3.22 percent intraday, Yiqiao Shenzhou rose 13.14 percent, Nanmo Bio rose 10.70 percent, Berry Genomics rose 10.02 percent, Biopsychus rose 8.02 percent, and PharmaBlock Sciences rose 5.61 percent. Industrial Securities believes that innovation plus globalization remains the main theme for the pharmaceutical sector throughout the year. Multinational pharmaceutical companies facing patent cliffs need external pipelines, while domestic drug companies' R&D efficiency advantages are becoming more prominent, and cooperation models are upgrading, representing an increase in China's innovative voice.

AstraZeneca agreed to invest $2 billion in Summit Therapeutics to test new cancer drug combinations, a stake that would give the biopharmaceutical company rights equivalent to roughly 12% of Summit's outstanding common shares. The companies plan to test AstraZeneca's sonesitatug vedotin alongside Summit's ivonescimab in gastrointestinal cancers, with each retaining the rights to its own medicine and room to pursue a broader clinical program if the partnership delivers. AstraZeneca shares were down about 0.7% at $164.95 at 9.55am EST on Tuesday. At that price, AstraZeneca trades 9.24% below its $181.75 GF Value estimate.

AstraZeneca agreed to make a $2 billion strategic equity investment in Summit Therapeutics, sending the biopharmaceutical company's shares up 17.1% in premarket trading. The investment supports a collaboration combining Summit's flagship bispecific antibody, ivonescimab, with AstraZeneca's oncology pipeline, and AstraZeneca will acquire convertible preferred shares at a price equivalent to $18.36 per common share, a 10% premium to Summit's five-day volume-weighted average price. Fair Isaac tumbled 15% after the Federal Housing Finance Agency announced changes to mortgage pricing that will introduce competition to FICO's longstanding role in the mortgage credit-scoring market; FHFA Director Bill Pulte said Fannie Mae and Freddie Mac will consolidate their separate pricing matrices into a single unified grid that will incorporate VantageScore alongside the traditional FICO Classic score. CarMax rose 3.7% after reporting fiscal second-quarter earnings of $1.16 per share, beating analyst expectations of 68 cents, with revenue of $7.88 billion topping forecasts of about $7.06 billion. AAR Corp. surged 6.9% after announcing an agreement to acquire a 65% controlling interest in MRO Holdings at an implied enterprise value of $4 billion, alongside adjusted diluted EPS of $1.49 and revenue of $918 million that beat expectations. Netflix rose 1.4% after Deutsche Bank upgraded the streaming giant to Buy from Hold with a $95 price target, while AbCellera Biologics gained 2.1% on a JPMorgan Overweight initiation with a $17 price target and Q32 Bio rose 9.4% ahead of a key clinical data presentation at the European Academy of Dermatology and Venereology Congress in Vienna beginning Sept. 30.

AstraZeneca announced a $2B equity investment in Summit Therapeutics and a clinical collaboration to develop new cancer treatments, sending Summit shares up 24%. Under the deal, AstraZeneca will purchase convertible preferred shares at a conversion price equivalent to $18.36 per common share, a 10% premium to Summit's five-day volume-weighted average price. Sangoma Technologies shares soared 35% after the company agreed to be acquired by an affiliate of BRC Group Holdings in a transaction valuing the firm at approximately $204M in enterprise value, with shareholders receiving $4.925 in cash plus 0.04767 of a BRC share per Sangoma share, implying total consideration of $5.225 per share. Navitas Semiconductor jumped 14% after saying it was selected by the U.S. federal government to develop next-generation 10 kV silicon carbide power semiconductor technology under the Army's ALATTIS program. Pharming shares slipped 2% after CEO and executive director Fabrice Chouraqui stepped down with immediate effect, with Chief Commercial Officer Leverne Marsh and CFO Kenneth Lynard appointed interim co-CEOs.

AstraZeneca has invested two billion US dollars, or £1.5 billion, in US pharmaceutical firm Summit Therapeutics as part of a cancer treatment research joint venture. The equity investment will help speed up development of Summit's experimental drug ivonescimab, which targets specific proteins to attack cancer cells and stop them growing. The two firms will collaborate on the medicine and research how it could be combined with AstraZeneca's treatments, particularly its sonesitatug vedotin drug, with trials in gastrointestinal cancer to begin imminently. Each company will contribute its respective medicine for the planned combination trials and jointly fund trial costs, while retaining development and commercial rights to its own medicines. Summit's shares soared by nearly a fifth after markets closed overnight in New York, while AstraZeneca's shares were 2% higher on Tuesday morning in London.

Dizal Pharmaceutical announced that it has received a $600 million upfront payment from AstraZeneca. Previously, on July 14, 2026, the two parties signed a license agreement for sunvozertinib, under which Dizal Pharmaceutical granted AstraZeneca exclusive global rights to develop and commercialize sunvozertinib. In addition to the $600 million upfront payment, the company will also receive up to $900 million in milestone payments tied to specific clinical development, regulatory approval, and sales achievements, as well as tiered royalties on global sales. Dizal Pharmaceutical said the funds have effectively strengthened its cash reserves and are expected to have a positive impact on its 2026 results and financial position. Sunvozertinib is an oral, irreversible, highly selective tyrosine kinase inhibitor independently developed by the company. Its use as a monotherapy in second-line and later settings for EGFR exon 20 insertion mutation non-small cell lung cancer has been approved in both China and the United States, and AstraZeneca will commercialize the drug in the U.S. in the fourth quarter of this year. In the first half of 2026, the company achieved operating revenue of 523 million yuan, up 47.24% year on year, while the net loss attributable to shareholders of the listed company was 210 million yuan, narrowing the loss by 167 million yuan compared with the same period last year.

China's innovative drug industry has welcomed another major licensing deal. Shanghai Sprout and Merck jointly announced a global exclusive licensing agreement for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor, with a potential total value of $2.13 billion, including an upfront payment of $400 million, with the remainder tied to development and commercialization milestones. Meanwhile, Summit Therapeutics, the overseas partner of Akeso, announced that AstraZeneca will make a $2 billion strategic equity investment in Summit and intends to lead clinical exploration of Akeso's first-in-class tumor immunotherapy 2.0 cornerstone drug ivonescimab in combination with AstraZeneca's Sonesitatug Vedotin for treating multiple gastrointestinal tumors. The two parties also signed a memorandum of understanding to further advance clinical exploration of ivonescimab combined with a range of AstraZeneca antibody-drug conjugates and other anti-tumor drugs. Boosted by the news, as of 10:01 a.m. on September 29, 2026, the STAR Market Biotech ETF managed by Penghua Fund, with ticker 588250, saw its underlying index, the SSE STAR Market Biomedical Index with code 000683, rise 1.10%. Among constituents, InventisBio rose 5.16%, Micro-Tech Nanjing rose 3.84%, Hotgen Biotech rose 3.13%, and Huiyu Pharmaceutical and Yound Biotechnology followed the gains. China Securities pointed out that the medical device sector has reached an inflection point in 2026, and stocks with improving performance are expected to see dual recovery in valuation and earnings. High-value consumables and in-vitro diagnostics segments are expected to gradually clear the impact of centralized procurement price cuts in the second half of the year, and leaders in niche tracks will accelerate growth.

AstraZeneca has submitted a New Drug Application to the US Food and Drug Administration for ORPATHYS, or savolitinib, plus TAGRISSO, or osimertinib, for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have MET overexpression or amplification and who progressed on or after an EGFR tyrosine kinase inhibitor therapy, HUTCHMED announced. The filing is supported by the global SAFFRON Phase III trial, the first global Phase III trial to demonstrate statistically significant and clinically meaningful improvements in progression-free survival and overall survival in this setting, versus doublet platinum-based chemotherapy in patients who progressed on TAGRISSO. SAFFRON enrolled 338 patients across 230 centers in 29 countries and builds on evidence from the SACHI Phase III and SAVANNAH Phase II trials, with results to be presented in a Presidential Symposium at the upcoming European Society for Medical Oncology Congress 2026. ORPATHYS is jointly developed by AstraZeneca and HUTCHMED and is commercialized by AstraZeneca; the combination is already approved in China based on SACHI and received a temporary authorization in Switzerland based on SAVANNAH. Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said the filing is an important step toward potentially bringing the biomarker-directed, chemotherapy-free oral combination to patients in the US.

Eccogene has received a $50 million milestone payment from AstraZeneca, triggered by the initiation of the global Phase 3 clinical program for elecoglipron, also known as AZD5004 or ECC5004. Elecoglipron is an investigational once-daily oral small molecule GLP-1 receptor agonist discovered by Eccogene and licensed to AstraZeneca outside Greater China in November 2023. The Phase 3 program includes the Embold trials in obesity or overweight with and without type 2 diabetes, the Eluminate trials in type 2 diabetes as monotherapy and in combination with dapagliflozin, and two Elevate outcome trials in heart failure with mildly reduced or preserved ejection fraction and chronic kidney disease. The Phase 3 start follows positive topline results from the Phase 2b VISTA and SOLSTICE trials, which showed 11.8% weight loss at 36 weeks in adults with obesity or overweight and a 1.9% HbA1c reduction at 26 weeks in adults with type 2 diabetes. Eccogene has now earned $295 million to date under the collaboration and remains eligible for future milestones and royalties, with the original deal including a $185 million upfront payment and up to $1.825 billion in total clinical, regulatory and commercial milestones.

AstraZeneca announced Wednesday that the European Commission approved its inhaler therapy Trixeo Aerosphere as a late-line maintenance option for asthma patients aged 12 years and older, expanding the drug's availability in the EU. The decision specifically covers patients whose symptoms remain insufficiently controlled despite prior therapy with a combination of a medium-dose inhaled corticosteroid and a long-acting beta2-agonist. Marketed as Breztri Aerosphere in the U.S., the triple-combination therapy is already available there for adults with chronic obstructive pulmonary disease. The latest approval follows a positive opinion in July from an expert panel of the EU drug regulator recommending the label expansion for asthma, a condition affecting nearly 43 million people in Europe.

AstraZeneca received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use for Enhertu and Klygefa in the European Union. The committee backed Enhertu as an adjuvant treatment option for early-stage HER2-positive breast cancer with a high risk of recurrence. It also supported Klygefa as an add-on therapy for generalised myasthenia gravis, targeting patients with a rare autoimmune condition. The next concrete waypoint for investors is the formal European Commission decisions following these September 2026 CHMP opinions, including the exact labels granted for Enhertu and Klygefa in the EU. Those label details and the timing of the decisions will shape how far AstraZeneca can extend usage into high-risk early breast cancer and anti-acetylcholine receptor positive gMG in the first wave of launches.

The AI Structural Biology Network, powered by Apheris, launched AISB Bind, a federated initiative in which AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson will collaboratively train an AI model to predict how small molecules bind to protein targets for virtual screening and lead optimization. The new initiative extends the network's first effort, which focused on protein-ligand structure prediction, where a co-folding model fine-tuned across more than 20,000 proprietary structures from active drug-discovery programs raised the share of high-quality predictions from 36% to 52%, outperforming public models and any model fine-tuned on a single partner's data alone. In AISB Bind, the four founding partners contribute three complementary types of data: experimentally determined structures, quantitative affinity and potency measurements, and high-throughput screening activity data, the last adding a large body of confirmed non-binders that is rarely available at industrial scale. Training runs through federated learning, so each partner's proprietary data stays within its own secure environment, with Apheris hosting the network and running the training and each partner receiving the resulting model to run and further tailor internally. Federated training begins in September 2026, with final models expected in early 2027, powered by the infrastructure of Apheris's technology partner, Amazon Web Services.

AstraZeneca and Daiichi Sankyo's Enhertu has been cleared for use by England's National Health Service for patients with HER2-low metastatic breast cancer, reversing an earlier NICE decision that rejected funding on cost-effectiveness grounds. NICE's revised recommendation follows changes to drug valuation methods and a U.S.-UK agreement aimed at aligning medicine prices, and around 1,000 women in England are expected to benefit annually. Enhertu carries a list price of £1,455 per 100 mg vial, although the financial terms agreed with NICE were not disclosed, and NICE cited clinical evidence showing a six-month survival benefit for some patients. The decision expands access in one of Europe's largest healthcare markets and comes as Enhertu is already a significant growth driver: combined sales reported by AstraZeneca and Daiichi Sankyo reached $2.96 billion in the first half of 2026, up 29% from $2.29 billion a year earlier, while AstraZeneca's own H1 alliance revenue from Enhertu rose to $1.06 billion from $834 million. In Europe, AstraZeneca reported $401 million of Enhertu revenue, up 28%, and combined global sales increased 36% in FY2025 to $4.98 billion, with AstraZeneca's alliance revenue reaching $1.80 billion versus $1.44 billion in 2024. The direct financial contribution from England may remain relatively limited given the roughly 1,000 patients expected annually and the undisclosed commercial terms, making the incremental revenue, margin, or cash-flow benefit difficult to quantify.

AstraZeneca announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of its rare-disease drug Klygefa, also known as gefurulimab, as an add-on therapy for adults with generalised myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. If approved, Klygefa would become the first and only dual-binding nanobody C5 inhibitor for that patient population in the European Union. The drug is already approved in Japan and certain other countries for specific adults with gMG, and is under regulatory review in the United States, China and some other countries for the same indication. The CHMP recommendation was supported by positive data from the pivotal phase III PREVAIL study, which met its primary endpoint by showing a treatment difference of -1.6 in the myasthenia gravis activities of daily living score at week 26 versus placebo, with clinically meaningful improvement seen as early as week one and sustained through week 26. About 85% of people living with gMG are AChR antibody-positive, and across five major European countries an estimated 82,500 people have gMG, including approximately 66,000 AChR antibody-positive patients.

AstraZeneca said the FDA accepted its regulatory filing for the investigational enzyme replacement therapy efzimfotase alfa in patients aged two years and older with hypophosphatasia, or HPP, and granted the application priority review, shortening the review period by four months, with a final decision expected during the first half of 2027. The filing is supported by data from three phase III studies: MULBERRY met its primary endpoint in treatment-naive children aged two to less than 12 years old, showing a significant improvement in bone health, and CHESTNUT showed that patients switching from Strensiq could maintain the benefits of treatment, while HICKORY did not meet its primary endpoint in treatment-naive individuals aged 12 years and older, though AstraZeneca reported a numerical improvement, particularly in patients with pediatric-onset disease. The company said efzimfotase alfa was generally well-tolerated with an acceptable safety profile across the three studies. The commercial angle rests on Strensiq, the established HPP treatment AstraZeneca gained through its 2021 acquisition of Alexion, which was approved by the FDA in 2015 as the first bone-targeted enzyme replacement therapy for HPP and generated $1.05 billion in sales in the first half of 2026, up 41% year over year. Efzimfotase alfa is designed to require lower injection volumes and substantially less frequent dosing, once every two weeks, compared with Strensiq's three- or six-times-weekly regimen. Elsewhere in the space, BioMarin Pharmaceutical entered HPP through its acquisition of Alesta Therapeutics, completed earlier this month, paying $275 million upfront with up to $215 million in additional milestone payments for ALE1, an oral small-molecule therapy in a phase I/IIa study, while Recursion Pharmaceuticals is developing the oral ENPP1 inhibitor REC-102, formerly REV102, which remains in IND-enabling studies with a data-driven decision on a phase I study expected before the end of this year.

AstraZeneca and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy, with 14.3 months median progression free survival and a 37% risk reduction versus pembrolizumab plus chemotherapy. Long-term follow-up data for TAGRISSO indicated eight-year survival benefits in early-stage EGFR-mutated lung cancer patients already on treatment protocols. Tozorakimab emerged as the first biologic to show efficacy in reducing exacerbations across a broad chronic obstructive pulmonary disease population in late-stage trials, with a 29% to 34% exacerbation reduction. Management has pointed to more than US$10b in potential peak risk adjusted revenue from new drugs, and investors will focus on US and EU COPD approval decisions ahead of the first quarter of 2027 Prescription Drug User Fee Act date. The article was produced by Simply Wall St.

AstraZeneca PLC released full results from two successful late-stage trials of tozorakimab, an experimental chronic obstructive pulmonary disease drug that reduced moderate and severe flare-ups by roughly 30% across a broad patient population. The two trials showed reductions in moderate-to-severe COPD exacerbations of 29% to 34%, with the highest-eosinophil subgroup seeing a 43% reduction, and benefits appearing regardless of eosinophil levels, smoking status, or disease severity. The biologic, which blocks the inflammatory protein IL-33, is under priority review at the FDA with a decision expected in the first quarter of 2027, and AstraZeneca forecasts more than $5 billion in peak annual sales, an estimate CEO Pascal Soriot said the drug's commercial potential could exceed. AstraZeneca believes tozorakimab could reach a broader group of COPD patients than existing biologics such as Regeneron and Sanofi's Dupixent and GSK's Nucala, which only target those with high eosinophil counts. The company's oncology and respiratory portfolio made $14.1 billion in first-half 2026 revenue, up 15% year over year, as AstraZeneca targets $80 billion in annual revenue by 2030, though the drug still needs FDA approval and faces patent-expiry pressure on established products including Farxiga and Brilinta.

London stocks closed higher on Thursday, September 17, with the FTSE 100 ending at 10,816.14 points, up 127.67 points, or 1.19%, hitting its highest level in more than a week. The gain came after the Bank of England voted 6 to 3 to keep interest rates at 3.75%, in line with market expectations, and announced it would suspend sales of UK government bonds for six months and halt long-dated bond sales altogether. The move followed a global bond selloff just days earlier that pushed the UK's 30-year borrowing cost to 5.96%, its highest since 1998. BoE Governor Andrew Bailey warned that prolonged conflict in the Middle East could make tighter monetary policy necessary. Data from LSEG showed investors had already priced in at least a 0.25% rate hike from the BoE this year. Rate-sensitive bank shares rose 1.6%, with HSBC and Standard Chartered leading the market with gains of 2% and 2.2% respectively. AstraZeneca rose about 2.4% after Chinese authorities said they would invest nearly 200 million yuan, or 29.81 million dollars, to upgrade its manufacturing base and supply chain in the city of Wuxi. Bytes Technology surged 12% after stronger-than-expected first-half results and an upgrade to its full-year gross profit growth forecast.

Onco360 has been selected by AstraZeneca as a national pharmacy partner for Etcamah, also known as camizestrant, the company announced. The therapy is indicated for adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of an ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test. Etcamah is an estrogen receptor antagonist that binds to the ligand-binding domain of ERα, antagonizing both wild-type and mutated ESR1 and inducing proteasome-dependent degradation of ERα without agonizing it. Its approval was based on the phase 3 SERENA-6 study, in which Etcamah plus a CDK4/6 inhibitor reduced the risk of disease progression or death by 56% versus an aromatase inhibitor plus a CDK4/6 inhibitor, with median PFS of 16 months versus 9.2 months and a hazard ratio of 0.44. The most common adverse reactions, occurring in at least 20% of patients, included decreased neutrophils, leukocytes, hemoglobin, lymphocytes and platelets, along with visual disturbances and fatigue.

The FDA granted accelerated approval to AstraZeneca's camizestrant, sold as Etcamah, for a genetically driven form of metastatic breast cancer, Bloomberg reported on September 5, 2026, despite an FDA advisory panel voting in April that the drug lacked patient benefit. The approval covers use alongside a CDK4/6 inhibitor for patients with an ESR1 gene mutation, based on a Phase III trial showing the combination cut the risk of disease progression or death by 56% compared with standard treatment. Median progression-free survival reached 16 months versus 9.2 months with standard treatment. Etcamah is already approved in more than 30 countries and is projected to make over $5 billion in peak annual sales. The accelerated approval requires AstraZeneca to complete confirmatory studies, and the Oncologic Drugs Advisory Committee voted 6-3 against the drug's risk-benefit profile in April, with several members questioning the trial design and whether the treatment would provide long-term benefit.

AstraZeneca has pledged to invest $15bn in China, deepening Western pharmaceutical ties with a country that has become a bona fide drug superpower even as Washington moves to sever them. The company's chief executive, Sir Pascal Soriot, announced the investment during Sir Keir Starmer's Beijing visit, building on existing manufacturing and research sites in Beijing, Shanghai, Wuxi, Taizhou and Qingdao; China is now AstraZeneca's second-largest market, accounting for roughly 12pc of global turnover, with around 17,000 employees and four advanced manufacturing sites. GSK has struck a series of partnerships with Chinese labs, including a $1.3bn pact with Hutchmed for the bulk of licensing rights to what it called first-in-class cancer treatments, and an alliance with Hengrui Pharma worth up to $12bn. Industry-wide licensing deals totalled $138bn last year, a nearly tenfold jump since 2021, according to PharmCube. The US Biosecure Act, signed into law in December, bars companies reliant on federal contracts from working with Chinese biotech firms tied to the military, and the proposed Biotech Investment National Security Act would subject licensing deals involving Chinese companies to national security reviews. China had 1,255 drugs at the research stage by 2024, a nearly eight-fold jump in less than a decade, against 1,441 in America and 400 in Europe.

AstraZeneca's TAGRISSO (osimertinib) demonstrated an unprecedented eight-year overall survival benefit in early-stage EGFR-mutated non-small cell lung cancer in the ADAURA Phase III trial, reducing the risk of death by 47% versus placebo in the primary population of Stages II-IIIA patients. In the overall trial population of Stages IB-IIIA, TAGRISSO reduced the risk of death by 48%, with an estimated 79% of TAGRISSO-treated patients alive at eight years versus 64% of those on placebo. The updated exploratory results, presented at the IASLC 2026 World Conference on Lung Cancer in Seoul and simultaneously published in the Journal of Thoracic Oncology, showed an estimated 74% of TAGRISSO-treated patients alive at eight years versus 58% on placebo in the primary population. Roy S. Herbst, principal investigator in the ADAURA Phase III trial, noted a 16 percentage point improvement in overall survival at eight years versus placebo, while Susan Galbraith, AstraZeneca's Executive Vice President of Oncology Haematology R&D, said the results reinforce TAGRISSO as the adjuvant standard of care and backbone therapy across stages of the disease. Separately, real-world evidence presented at the conference from a retrospective cohort study of US patients with early-stage EGFRm NSCLC showed that early discontinuation of TAGRISSO before completing the three-year treatment course more than doubled the risk of disease recurrence or death.